Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult female and male patients aged =18 years or adults according to age of majority as defined by the local regulations on index date 2. Patient or next of kin/legal representative (for deceased patients at study entry unless a waiver is granted) willing and able to provide written or electronic informed consent according to the local regulations, where applicable 3. Patients diagnosed with primary stage IA to IIIB NSCLC as per seventh edition AJCC whose tumour was deemed resectable between 01 January 2013 and 31 December 2017 and followed up until at least 31 December 2020 as per the medical records with availability of at least 12 months of follow-up data from the index date (date of diagnosis of early-stage [IA to stage IIIB] resectable NSCLC) unless patient died within 12 months of diagnosis.
Exclusion criteria
Exclusion criteria: 1.Patients with a concomitant cancer at the time of diagnosis of NSCLC, except for nonmetastatic nonmelanoma skin cancers, or in situ or benign neoplasms; a cancer will be considered concomitant if it occurs within 5 years of NSCLC diagnosis 2. Patients diagnosed with stage IV NSCLC 3. Histology of the tumour is small cell lung cancer, neuroendocrine in origin, or a mixed histologic type with small cell and non-small cell lung cancers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Proportion of patients overall and as per clinical and pathologic staging (seventh edition of the tumour nodes metastases [TNM] classification for lung cancer [AJCC]) who underwent either of the following treatment modalities: o Surgery only o Neo-adjuvant therapy (chemo+/-radiotherapy) only o Adjuvant therapy (chemo+/-radiotherapy) only o Neo-adjuvant and adjuvant therapies 2. Duration of treatment for each treatment regimen in neo-adjuvant and adjuvant treatment settings, dose of each agent, and reason(s) for stopping treatment in each setting 3. 3-year survival rate (overall, and as per clinical and pathologic staging) defined as percentage of patients confirmed to be alive at 3 years from the index date.Timepoint: one-time | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic and clinical-pathological characteristics (overall and as per treatment modalities) Survival outcomes Prevalence of EGFR mutations and PD-L1 expression Real-world OS within the following subgroups: o Age (60 years, =60 to 80 years, and =80 years) o Clinico-pathologic stage of NSCLC as per seventh edition AJCC (IA, IB, IIA, IIB, IIIA, IIIB) with lymph node metastasis status (N0, N1, and N2) o EGFR mutation status (positive/negative) o PD-L1 status (1%, =1% to 25%, =25% to 50%, and =50%) Proportion of patients biomarker testing strategies Proportion of patients receiving neo-adjuvant and/or adjuvant treatments Proportion of patients undergoing each type of surgery and associated outcomes Compliance to neo-adjuvant and/adjuvant treatmentTimepoint: one-time | — |
Countries
Australia, Brazil, Egypt, Hong Kong, India, Kuwait, Qatar, Saudi Arabia, Turkey, United Arab Emirates
Contacts
Public ContactMr Amit Kumar
AstraZeneca Pharma India Ltd
Outcome results
None listed